{"id":679,"date":"2026-05-14T16:20:41","date_gmt":"2026-05-14T15:20:41","guid":{"rendered":"http:\/\/seamlessbio.de\/?page_id=679"},"modified":"2026-06-21T19:16:39","modified_gmt":"2026-06-21T18:16:39","slug":"dmpk-transporter-kit","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/dmpk-transporter-kit\/","title":{"rendered":"ABC-Transporter-Vesikel-Kits"},"content":{"rendered":"
\n\t\t\t\t
\n \t\t
\n\t\t\t\t\t
\n
\n\n
\n Startseite<\/a>\n \/<\/span>\n DMPK Transporter Kit<\/strong>\n <\/div>\n\n
\n
\n SeamlessBio \u2014 DMPK \/ Assays<\/span>\n

Cell4Pharma ABC Transporter Vesicle Kits<\/h1>\n

\n HEK293-derived inside-out membrane vesicle kits for the full\n panel of regulatory ABC transporters \u2014 BSEP, BCRP, P-gp and\n MRP1\u2013MRP5\/MRP8 \u2014 for DDI studies and DILI risk assessment per\n FDA and EMA guidance.\n <\/p>\n

\n Informationen anfordern<\/a>\n Im Shop ansehen<\/a>\n <\/div>\n <\/div>\n
\n \"Cell4Pharma\n
Platzhalter f\u00fcr Produktbild<\/div>\n <\/div>\n <\/div>\n\n
\n\n
\n 01<\/span>\n

Full Regulatory Panel<\/h3>\n

\n BSEP, BCRP, P-gp and MRP1\u2013MRP5\/MRP8 \u2014 the complete set of\n transporters referenced in FDA and EMA DDI guidance.\n <\/p>\n <\/div>\n\n

\n 02<\/span>\n

100 Reactions per Kit<\/h3>\n

\n Each kit is sized for 100 reactions in a 96-well plate format,\n suitable for IC50 determination and screening.\n <\/p>\n <\/div>\n\n

\n 03<\/span>\n

Inside-Out HEK293 Vesicles<\/h3>\n

\n Confirmed transporter expression and orientation for\n reliable, reproducible transport data.\n <\/p>\n <\/div>\n\n

\n 04<\/span>\n

Assay Service Available<\/h3>\n

\n Don't have in-house capacity? Our ciPTEC assay service can run\n the full transporter panel for you.\n <\/p>\n <\/div>\n\n <\/div>\n\n

\n\n
\n

Why ABC transporter testing matters in DMPK programs<\/h2>\n

\n ABC (ATP-binding cassette) transporters mediate the efflux of\n drugs and metabolites across cell membranes, and inhibition of\n key transporters \u2014 particularly BSEP, BCRP and P-gp \u2014 is\n mechanistically linked to drug-induced liver injury (DILI) and\n clinically relevant drug-drug interactions (DDI). FDA and EMA\n guidance both recommend transporter inhibition testing as part\n of standard DMPK characterisation.\n <\/p>\n

\n The vesicle-based assay format uses HEK293-derived inside-out\n membrane vesicles with confirmed transporter expression,\n allowing direct measurement of transporter-mediated substrate\n uptake in the presence and absence of test compounds \u2014 the\n basis for IC50 determination and single-concentration screening.\n <\/p>\n

\n Because inhibition of multiple transporters can compound DILI\n risk \u2014 for example, BSEP inhibition together with MRP2, MRP3 or\n MRP4 impairs the compensatory bile acid efflux pathways that\n partially protect hepatocytes \u2014 a full panel typically gives a\n more complete risk picture than testing BSEP in isolation.\n <\/p>\n <\/div>\n\n

\n

Typical applications<\/h3>\n